Compounds > wr 194965
Page last updated: 2024-12-07

wr 194965

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WR 194965: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129635
CHEMBL ID174301
SCHEMBL ID15674488
MeSH IDM0130296

Synonyms (16)

Synonym
NCI60_002600 ,
69121-82-0
CHEMBL174301
4-tert-butyl-2-[(tert-butylamino)methyl]-6-(4-chlorophenyl)phenol
(1,1'-biphenyl)-2-ol, 4'-chloro-5-(1,1-dimethylethyl)-3-(((1,1-dimethylethyl)amino)methyl)-
wr 194,965
wr 194965
wr-194,965
DTXSID90219184
SCHEMBL15674488
wr-194965
PD160560
4RD6V6BLX8
4'-chloro-5-(1,1-dimethylethyl)-3-[[(1,1-dimethylethyl)amino]methyl][1,1'-biphenyl]-2-ol
[1,1'-biphenyl]-2-ol, 4'-chloro-5-(1,1-dimethylethyl)-3-[[(1,1-dimethylethyl)amino]methyl]-
butyl)-2-(tert-butylaminomethyl)-6-(4-chlorophenyl)phenol, 4-(tert-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID135291Antimalarial activity as 60-day survivors in Plasmodium berghei infected mice (Mus musculus) after single 160mg/kg subcutaneous dose 72 hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129942Difference in mean survival time in mice (Mus musculus) (control = 6.2 days) after single 40mg/kg subcutaneous dose 72hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129945Change in mean survival time for control (average of 6.2 days) versus treated mice (Mus musculus) 72 hrs after 80 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID135296Antimalarial activity, administered as a single subcutaneous dose of 640 mg/kg, 72 hrs post infection measured as number of mice (Mus musculus) surviving at 60 days post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID135293Antimalarial activity as 60-day survivors in infected mice (Mus musculus) after single 320mg/kg subcutaneous dose 72 hr post infection1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
AID129940Change in mean survival time for control (average 6.2 days) versus treated mice (Mus musculus) 72 hrs after 20 mg/kg subcutaneous dose1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		2.3820aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.6630aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
pyrimethamine
Maloprim: contains above 2 cpds		2.3820aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
halofantrine
halofantrine: used in treatment of mild to moderate acute malaria		2.6630phenanthrenes
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		1.9710organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
tebuquine
[no description available]		2.6530
wr 99210
BRL 6231: RN given refers to parent cpd; NM & N1 refer to HCl; synonym BRL 51084 refers to (mono-HBr); structure		1.9710
wr 184806
WR 184806: internal std for chromatographic anal of mefluquine; RN given refers to (+-)-isomer; structure given in first source		1.9710
quinidine
Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.		1.9710cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
wr 225448
WR 225448: used as prophylaxis for Plasmodium yoelii infections; structure given in first source		2.3720
sesquiterpenes
[no description available]		1.9710
enpiroline
enpiroline: structure		2.6630
quinine
[no description available]		2.3820cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
alpha-(2-piperidyl)-3,6-bis(trifluoromethyl)-9-phenanthrenemethanol
alpha-(2-piperidyl)-3,6-bis(trifluoromethyl)-9-phenanthrenemethanol: structure		1.9710
mefloquine
Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.		2.8940
amodiaquine hydrochloride
[no description available]		1.9610
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.6630
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Plasmodium
[description not available]		02.3720
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		07.3720